A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Nademanee, Auayporn; Forman, Stephen J.; Molina, Arturo; Fung, Henry C.; Smith, David; Dagis, Andrew; Kwok, Cheuk S.; Yamauchi, Dave; Anderson, Aaron S.; Falk, Peter; Krishnan, Amrita; Kirschbaum, Mark; Kogut, Neil; Nakamura, Ryotaro; O’Donnell, Margaret; Parker, Pablo; Popplewell, Leslie; Pullarkat, Vinod; Rodríguez, Roberto; Sahebi, Firoozeh; Smith, Eileen; Snyder, David S.; Stein, Anthony S.; Spielberger, Ricardo; Zain, Jasmine; White, Christine; Raubitschek, Andrew

doi:10.1182/blood-2005-03-1310

Cited by 191 publications

(99 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 The initial studies using radioimmunotherapy in combination with high-dose chemotherapy and autologous SCT show promising results. [18][19][20][21][22] In this study, we explored the use of standard-dose Zevalin combined with RIC and allogeneic SCT in patients with chemorefractory lymphoma expected to have poor outcome with standard SCT.…”

Section: Introductionmentioning

confidence: 99%

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Shimoni

Zwas

Oksman

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Shimoni

Zwas

Oksman

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Efforts should be made to include these patients in clinical trials, perhaps testing new drugs in the relapsing setting or the use of radioimmunoconjugates as part of the conditioning regimen. [33][34][35] The prognostic system proposed here is practical and powerful but needs to be validated in an independent cohort. Although clinically relevant, a prognostic model constituted by IPI-R and TTR will not be perfect, in part because these markers are likely surrogates of a tumor's capacity to proliferate, migrate and resist the lethaal effects of chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

Costa

Micallef

Inwards

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

We explored the concomitant effect of the International Prognostic Index at the time of relapse (IPI-R) and the time from initial diagnosis to relapse (TTR) on outcome of 80 uniformly treated patients receiving BEAM conditioning followed by SCT for relapsed, chemosensitive diffuse large B-cell lymphoma. Median age at the time of transplantation was 62 years (range 26-77). Median follow-up of survivors was 31.4 months. Median overall survival (OS) from the time of transplant for patients with TTR 418 months vs p18 months was not reached and 50 months, respectively (P ¼ 0.01). Median OS for patients with IPI-R X3 was 23.3 months and not reached for patients with IPI-R o3 (P ¼ 0.01). These factors were independent in multivariate analysis with relative risk for death of 0.91 (0.80-0.99; P ¼ 0.04) for each 6-month increment in TTR and 0.63 (0.42-0.96; P ¼ 0.03) for IPI-R o3. TTR p18 months and IPI-R X3 were combined in a prognostic system where patients with none (n ¼ 32), one (n ¼ 39) or two (n ¼ 9) of these factors had median OS not reached, of 50 and 5 months, respectively (Po0.01). Patients with early, high IPI-R relapse after first-line therapy have a dismal outcome with SCT and should receive experimental therapies.

show abstract

“…These findings indicate that the use of novel therapeutics should be explored in attempts to improve the outcome in such patients. Recently, the use of immunotherapy or radioimmunotherapy (Rituximab, Y-ibritumomab) as part of the conditioning regimen for ASCT has produced promising results with improved disease control (24,25). The results of these newer approaches are expected to improve the outcome in these patients.…”

Section: Discussionmentioning

confidence: 99%

Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma

Hong

Woo

et al. 2007

Cancer Res Treat

View full text Add to dashboard Cite

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Cited by 191 publications

References 28 publications

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma

Contact Info

Product

Resources

About